



Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology

VIENNA, AUSTRIA, July 19, 2022 -- Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent [US11352619 B2](#), covering Ribbon Biolabs' novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology.

"Our novel method of fast, accurate, cost-effective DNA synthesis constitutes the basis of Ribbon Biolabs' proprietary capabilities, and the grant of this patent serves as a validation of our highly differentiated solution for synthetic biology," commented **Harold P. de Vladar, CEO and founder of Ribbon Biolabs**. "Previous methods for automated DNA synthesis have been limited in their applicability due to restricted lengths possible to produce and extended development timelines. We look forward to the further expansion of our intellectual property portfolio and our growing collaborations focused on driving innovation in the biotechnology, biopharma and academic research arenas."

Ribbon Biolabs' novel approach to synthesizing DNA as described in the patent comprises a pre-built library of oligonucleotides, or shorter genetic sequences, that has been streamlined for efficient access, with reduced time and cost constraints that are further enhanced by an assembly workflow producing long polynucleotides accurately and without mismatches. This method optimizes the throughput time required to synthesize target DNA which has enabled the company to produce lengths beyond 10,000 base pairs efficiently and with high speed, including the recent successful synthesization of a 20,000 bp molecule for an undisclosed pharma client.

About Ribbon Biolabs

Ribbon Biolabs is a synthetic biology company advancing a new technology for the automated synthesis of long DNA molecules to enable innovation in the life sciences. With its proprietary technology in place, Ribbon Biolabs aims to be an inflection point in the continuing growth of the Bio-Economy by becoming the leading partner for long DNA molecules.

CONTACTS:

Ribbon Biolabs

Gabriele Schaller

PR@ribbonbiolabs.com



Trophic Communications

Eva Mulder or Joel Hornby

+31 6 52 33 15 79 or +49 160 9081 6161

ribbon@trophic.eu